Active Compound in Popular Heartburn Drug Pepcid Being Tested for COVID-19 Treatment
|
By HospiMedica International staff writers Posted on 29 Apr 2020 |
|
Illustration
A trial for famotidine, the active compound in the over-the-counter heartburn medication Pepcid, is underway at the Feinstein Institutes for Medical Research (Manhasset, NY, USA) to study if the drug can make a difference in the treatment of COVID-19 patients.
The researchers decided to conduct a drug trial for famotidine after encouraging reports from China. A review of 6,212 COVID-19 patient records revealed that a large number of survivors had been experiencing chronic heartburn and were taking famotidine instead of omeprazole (Prilosec) which is more expensive and preferred in the US and among the wealthier population in China. Hospitalized COVID-19 patients who were taking famotidine seemed to have a lower death rate of 14% as against 27% for patients who were not taking the drug.
Additionally, molecular modeling results also suggested that famotidine, which appears to bind to a key enzyme in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could deliver results. Famotidine is believed to bind to an enzyme critical to COVID-19. Similar to how protease inhibitors, which are used to treat HIV, stop the virus, famotidine’s structure can stop the coronavirus from replicating, at least theoretically.
The Feinstein Institutes for Medical Research received clearance from the US Food and Drug Administration to conduct a trial using the intravenous version of famotidine. In addition to Gilead Sciences’ remdesivir and the anti-malarial drug hydroxychloroquine, the researchers are now also assessing famotidine in a small clinical trial which has enrolled 187 critical COVID-19 patients so far, including several on ventilators, and aims for a total of 1174 people. In the trial the patients are being intravenously administered nine times the amount of famotidine that a person would normally take to treat heartburn,
The researchers have been keeping the clinical trial of famotidine under wraps to ensure sufficient supply for their study, as well as avoid a rush to medication stores for the drug which would deny people with heartburn or stomach ulcers access to the drug.
Related Links:
Feinstein Institutes for Medical Research
The researchers decided to conduct a drug trial for famotidine after encouraging reports from China. A review of 6,212 COVID-19 patient records revealed that a large number of survivors had been experiencing chronic heartburn and were taking famotidine instead of omeprazole (Prilosec) which is more expensive and preferred in the US and among the wealthier population in China. Hospitalized COVID-19 patients who were taking famotidine seemed to have a lower death rate of 14% as against 27% for patients who were not taking the drug.
Additionally, molecular modeling results also suggested that famotidine, which appears to bind to a key enzyme in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), could deliver results. Famotidine is believed to bind to an enzyme critical to COVID-19. Similar to how protease inhibitors, which are used to treat HIV, stop the virus, famotidine’s structure can stop the coronavirus from replicating, at least theoretically.
The Feinstein Institutes for Medical Research received clearance from the US Food and Drug Administration to conduct a trial using the intravenous version of famotidine. In addition to Gilead Sciences’ remdesivir and the anti-malarial drug hydroxychloroquine, the researchers are now also assessing famotidine in a small clinical trial which has enrolled 187 critical COVID-19 patients so far, including several on ventilators, and aims for a total of 1174 people. In the trial the patients are being intravenously administered nine times the amount of famotidine that a person would normally take to treat heartburn,
The researchers have been keeping the clinical trial of famotidine under wraps to ensure sufficient supply for their study, as well as avoid a rush to medication stores for the drug which would deny people with heartburn or stomach ulcers access to the drug.
Related Links:
Feinstein Institutes for Medical Research
Gold Member
12-Channel ECG
CM1200B
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Patient Monitor
IntelliVue MP5SC
New
VTE Prevention System
Flowtron ACS900
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Critical Care
view channel
3D Printed Functional Human Islets Could Transform Type 1 Diabetes Treatment
Type 1 diabetes (T1D) is a chronic condition in which the body’s immune system destroys insulin-producing cells in the pancreas, requiring patients to rely on regular insulin injections to manage blood sugar.... Read more
AI Model Predicts ICU mortality in Heart Failure Patients
Currently, heart failure has emerged as a significant complication during the later stages of various cardiovascular disorders. In the Intensive Care Unit (ICU), patients with heart failure often experience... Read more
Surgical Techniques
view channel
Breakthrough Polymer Significantly Improves Safety of Implantable Medical Devices
Every year, millions of patients receive implantable cardiovascular devices such as arterial and venous catheters, pacemaker leads, artificial hearts, and vascular prostheses. These devices, typically... Read more
First-Ever Technology Makes Blood Translucent During Surgery
No matter the discipline or scale, bleeding is a regular part of any surgery and can create several challenges. In operating room imaging, seeing through blood in real-time during a surgery has been a... Read more
Tibia Nailing System with Novel Side-Specific Nails to Revolutionize Fracture Surgery
Smith+Nephew (Hull, UK;) has launched its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the... Read more
Patient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Smartwatches Could Detect Congestive Heart Failure
Diagnosing congestive heart failure (CHF) typically requires expensive and time-consuming imaging techniques like echocardiography, also known as cardiac ultrasound. Previously, detecting CHF by analyzing... Read more
Business
view channel
Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies
A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
